Literature DB >> 35700410

Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy.

Maria I Stamou1, Christopher Chen2, Seth A Wander3, Jeffrey G Supko4, Dejan Juric4, Aditya Bardia3, Deborah J Wexler5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35700410      PMCID： PMC9384915          DOI： 10.1200/PO.21.00428

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  36 in total

1.  Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.

Authors:  Naifa L Busaidy; Azeez Farooki; Afshin Dowlati; John P Perentesis; Janet E Dancey; Laurence A Doyle; Joanna M Brell; Lillian L Siu
Journal:  J Clin Oncol       Date:  2012-07-09       Impact factor: 44.544

2.  Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005).

Authors:  Ramesh K Ramanathan; Shannon L McDonough; Hagen F Kennecke; Syma Iqbal; Joaquina C Baranda; Tara E Seery; Howard J Lim; Aram F Hezel; Gina M Vaccaro; Charles D Blanke
Journal:  Cancer       Date:  2015-03-30       Impact factor: 6.860

Review 3.  Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.

Authors:  Jonathan W Goldman; Melody A Mendenhall; Sarah R Rettinger
Journal:  Oncologist       Date:  2016-07-29

4.  Hypothalamic K(ATP) channels control hepatic glucose production.

Authors:  Alessandro Pocai; Tony K T Lam; Roger Gutierrez-Juarez; Silvana Obici; Gary J Schwartz; Joseph Bryan; Lydia Aguilar-Bryan; Luciano Rossetti
Journal:  Nature       Date:  2005-04-21       Impact factor: 49.962

5.  Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.

Authors:  Dejan Juric; Filip Janku; Jordi Rodón; Howard A Burris; Ingrid A Mayer; Martin Schuler; Ruth Seggewiss-Bernhardt; Marta Gil-Martin; Mark R Middleton; José Baselga; Douglas Bootle; David Demanse; Lars Blumenstein; Karl Schumacher; Alan Huang; Cornelia Quadt; Hope S Rugo
Journal:  JAMA Oncol       Date:  2019-02-14       Impact factor: 31.777

6.  An activating mutation of AKT2 and human hypoglycemia.

Authors:  K Hussain; B Challis; N Rocha; F Payne; M Minic; A Thompson; A Daly; C Scott; J Harris; B J L Smillie; D B Savage; U Ramaswami; P De Lonlay; S O'Rahilly; I Barroso; R K Semple
Journal:  Science       Date:  2011-10-06       Impact factor: 47.728

7.  A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer.

Authors:  Komal Jhaveri; Joshua Z Drago; Payal Deepak Shah; Rui Wang; Fresia Pareja; Fanni Ratzon; Alexia Iasonos; Sujata Patil; Neal Rosen; Monica N Fornier; Nancy T Sklarin; Sarat Chandarlapaty; Shanu Modi
Journal:  Clin Cancer Res       Date:  2021-05-04       Impact factor: 12.531

8.  Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.

Authors:  Timothy A Yap; Li Yan; Amita Patnaik; Nina Tunariu; Andrea Biondo; Ivy Fearen; Kyriakos P Papadopoulos; David Olmos; Richard Baird; Liliana Delgado; Ernestina Tetteh; Robert A Beckman; Lisa Lupinacci; Ruth Riisnaes; Shaun Decordova; Simon P Heaton; Karen Swales; Nandita M deSouza; Martin O Leach; Michelle D Garrett; Daniel M Sullivan; Johann S de Bono; Anthony W Tolcher
Journal:  Clin Cancer Res       Date:  2014-09-19       Impact factor: 12.531

9.  Safety and pharmacokinetics of motesanib in combination with panitumumab and gemcitabine-Cisplatin in patients with advanced cancer.

Authors:  Howard Burris; Joe Stephenson; Gregory A Otterson; Mark Stein; Jesse McGreivy; Yu-Nien Sun; Megan Ingram; Yining Ye; Lee S Schwartzberg
Journal:  J Oncol       Date:  2011-04-14       Impact factor: 4.375

10.  Suppression of insulin feedback enhances the efficacy of PI3K inhibitors.

Authors:  Benjamin D Hopkins; Chantal Pauli; Xing Du; Diana G Wang; Xiang Li; David Wu; Solomon C Amadiume; Marcus D Goncalves; Cindy Hodakoski; Mark R Lundquist; Rohan Bareja; Yan Ma; Emily M Harris; Andrea Sboner; Himisha Beltran; Mark A Rubin; Siddhartha Mukherjee; Lewis C Cantley
Journal:  Nature       Date:  2018-07-04       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.